|
|
Clinical prognostic factors in patients with
malignant glioma treated with combined modality approach
Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J, Nikolic N
Department of Oncology, University Hospital, Kragujevac,
Yugoslavia.
The impact of various clinical pretreatment prognostic factors in patients with
malignant glioma treated with a combined modality approach was investigated in
229 patients treated on four consecutive prospective phase II studies.
The median survival time for all 229 patients is 14 months, and 2- and 5-year
survival rates are 34%, and 9%, respectively.
The median time to tumor progression is 14 months, and 2- and 5-year
progression-free survival rates are 32%, and 9%, respectively.
Females did better than males, while patients 55 years or less did better than
those more than 55 years.
Patients with Karnofsky performance status (KPS) 80 to 100 did better than those
with KPS 50 to 70 as well as did patients having preoperative tumor sizes 4 cm
or less when compared to those with larger tumors.
Frontal tumor location as well as more extensive surgery favorably influenced
survival.
Patients harboring anaplastic astrocytoma fared significantly better than those
with glioblastoma multiforme.
Both univariate and multivariate Cox analyses confirmed independent influence of
these prognosticators.
When progression-free survival was used as an endpoint, all seven variables
remained independent prognosticators.
This study showed that sex, age, KPS, tumor size, tumor location, histology, and
extent of surgery are independent prognosticators in patients with malignant
glioma treated with combined modality approach.
PMID: 15057161 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15057161
|
